323 related articles for article (PubMed ID: 27255162)
1. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of pleomorphic liposarcomatous differentiation in malignant phyllodes tumor of the breast: A case report.
Zhou P; Zhang Q; Zhu J; Li P
Pathol Res Pract; 2021 Aug; 224():153489. PubMed ID: 34091389
[TBL] [Abstract][Full Text] [Related]
3. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
Gatalica Z; Vranic S; Ghazalpour A; Xiu J; Ocal IT; McGill J; Bender RP; Discianno E; Schlum A; Sanati S; Palazzo J; Reddy S; Pockaj B
Oncotarget; 2016 Jan; 7(2):1707-16. PubMed ID: 26625196
[TBL] [Abstract][Full Text] [Related]
4. Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification.
Lyle PL; Bridge JA; Simpson JF; Cates JM; Sanders ME
Histopathology; 2016 Jun; 68(7):1040-5. PubMed ID: 26542423
[TBL] [Abstract][Full Text] [Related]
5. Genomic characterisation of breast fibroepithelial lesions in an international cohort.
Md Nasir ND; Ng CCY; Rajasegaran V; Wong SF; Liu W; Ng GXP; Lee JY; Guan P; Lim JQ; Thike AA; Koh VCY; Loke BN; Chang KTE; Gudi MA; Lian DWQ; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Tan P; Teh BT; Tan PH
J Pathol; 2019 Dec; 249(4):447-460. PubMed ID: 31411343
[TBL] [Abstract][Full Text] [Related]
6. Heterologous Liposarcomatous Differentiation in Malignant Phyllodes Tumor is Histologically Similar but Immunohistochemically and Molecularly Distinct from Well-differentiated Liposarcoma of Soft Tissue.
Inyang A; Thomas DG; Jorns J
Breast J; 2016 May; 22(3):282-6. PubMed ID: 26843318
[TBL] [Abstract][Full Text] [Related]
7. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
[TBL] [Abstract][Full Text] [Related]
8. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
[TBL] [Abstract][Full Text] [Related]
9. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
[TBL] [Abstract][Full Text] [Related]
11. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
[TBL] [Abstract][Full Text] [Related]
12. Analysis of recurrent molecular alterations in phyllodes tumour of breast: insights into prognosis and pathogenesis.
Tsang JY; Shao Y; Poon IK; Ni YB; Kwan JS; Chow C; Shea KH; Tse GM
Pathology; 2022 Oct; 54(6):678-685. PubMed ID: 35691725
[TBL] [Abstract][Full Text] [Related]
13. Genomic landscapes of breast fibroepithelial tumors.
Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S
Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235
[TBL] [Abstract][Full Text] [Related]
15. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
16. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions.
Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J
Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441
[TBL] [Abstract][Full Text] [Related]
17. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
[TBL] [Abstract][Full Text] [Related]
18. Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study.
Lv S; Niu Y; Wei L; Liu Q; Wang X; Chen Y
Breast Cancer Res Treat; 2008 Dec; 112(3):411-8. PubMed ID: 18189161
[TBL] [Abstract][Full Text] [Related]
19. Fibroepithelial lesions; The WHO spectrum.
Krings G; Bean GR; Chen YY
Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]